Antiger Therapeutics Inc.
St. Louis, MO
- UEI
- WSY4SWA56WQ7
- CAGE
- 9KAS0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4340 Duncan Ave #284, St. Louis, MO 63110, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Peptide-HLA-DQ8 biologics for antigen-specific therapy in type 1 diabetes - project summary/abstract antiger… | National Institute of Allergy and Infectious Diseases | $606,548 | |
| Peptide-HLA-DQ2 biologics for antigen-specific therapy in celiac disease - project summary/abstract antiger therapeutics… | National Institute of Allergy and Infectious Diseases | $293,680 | |
| Class II human leukocyte antigen biologics for antibody-mediated graft rejection. - project summary/abstract the mission… | National Institute of Allergy and Infectious Diseases | $272,503 |
About Antiger Therapeutics Inc.
Antiger Therapeutics Inc. is a startup biotech company located in St. Louis, Missouri, specializing in engineering recombinant human leukocyte antigens (HLA) and membrane proteins. Registered in SAM.gov since February 2022, the company is classified as a minority-owned, woman-owned, and for-profit organization. Antiger Therapeutics focuses on developing targeted immunotherapies for complex autoimmune diseases, leveraging innovative biological engineering techniques to create precise therapeutic interventions that selectively target aberrant immune responses.
The company has secured multiple Project Grants from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), each targeting specific autoimmune conditions. These grants include a $303,274 award for developing targeted immunotherapies for Type 1 Diabetes (T1D) using Peptide-HLA-DQ8 complex biologics, a grant for creating Peptide-HLA-DQ2 biologics to address Celiac Disease, and a project focused on developing Class II Human Leukocyte Antigen biologics to mitigate antibody-mediated graft rejection. Each grant demonstrates Antiger Therapeutics' core approach of engineering sophisticated biological solutions that can selectively block pathogenic immune responses, with the ultimate goal of preventing or reversing chronic autoimmune conditions. The company's technical innovations include disulfide bond engineering and producing full-length membrane proteins to overcome challenges in assembling complex protein structures.
Quick answers
What is Antiger Therapeutics Inc.'s UEI?
Antiger Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is WSY4SWA56WQ7.
What is Antiger Therapeutics Inc.'s CAGE code?
Antiger Therapeutics Inc.'s CAGE code is 9KAS0.
What is Antiger Therapeutics Inc.'s primary NAICS code?
Antiger Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Antiger Therapeutics Inc. located?
Antiger Therapeutics Inc.'s physical address in SAM.gov is 4340 Duncan Ave #284, St. Louis, MO 63110, USA.
Is Antiger Therapeutics Inc. registered in SAM.gov?
Yes. Antiger Therapeutics Inc.'s SAM.gov registration is active through March 27, 2027.
What is Antiger Therapeutics Inc.'s most recent federal award?
Antiger Therapeutics Inc.'s most recent federal grant award is Peptide-HLA-DQ8 biologics for antigen-specific therapy in type 1 diabetes - project summary/abstract antiger… (R43AI183983), from National Institute of Allergy and Infectious Diseases, on August 11, 2025.
On GovTribe
See Antiger Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors